trending Market Intelligence /marketintelligence/en/news-insights/trending/yytscb31oe63nxffalez8a2 content esgSubNav
In This List

Akari Therapeutics gets Nasdaq noncompliance notice

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Akari Therapeutics gets Nasdaq noncompliance notice

Akari Therapeutics PLC said it fell out of compliance with a Nasdaq listing requirement after failing to file its annual report for the year ended Dec. 31, 2017, on time.

The biopharmaceutical company has until Nov. 12 to regain compliance.

Akari's CEO recently resigned following an internal investigation that revealed he used the company's credit card for personal use.

Akari said it found David Solomon violating the drugmaker's policies after incurring personal charges on the company's corporate credit cards.